Tradipitant Treatment for Atopic Dermatitis via Genotype Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atopic dermatitis and chronic pruritus are inadequate in addressing the underlying pathophysiology of intense itch, particularly in patients with high IgE levels, where traditional therapies often fail to provide significant relief.
Innovation Solution
Administering tradipitant, a selective neurokinin-1 receptor antagonist, tailored to individual patient genotypes associated with high IgE levels or positive treatment responses, with dosages adjusted based on specific SNP markers and baseline IgE levels to optimize efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional therapies are used to treat atopic dermatitis, then treatment coverage is broad, but efficacy in patients with high IgE levels is insufficient
Solution Approach 1:
The patent applies local quality by tailoring treatment to specific patient subgroups based on their IgE levels and genetic profiles. Instead of uniform treatment, patients are stratified into high-IgE and low-IgE groups, with tradipitant specifically targeted to the high-IgE population who demonstrate greater treatment response, thereby optimizing efficacy for the right patient population
Solution Approach 2:
The patent utilizes parameter changes by incorporating genetic markers (SNPs) and IgE level thresholds as selection criteria. Treatment decisions are based on quantitative parameters such as IgE concentration levels and specific genotype presence, allowing dynamic adaptation of therapy based on measured patient parameters
2Adaptability or versatility
If tradipitant is administered to all patients with atopic dermatitis, then treatment coverage is maximized, but treatment cost and complexity increase
Solution Approach 1:
The patent applies preliminary action by performing genotyping and IgE level assessment before initiating tradipitant treatment. Patients are pre-screened for high-IgE status and relevant genetic markers, allowing treatment to be prescribed only to those most likely to benefit, thereby simplifying the overall treatment protocol by avoiding unnecessary treatments in low-responders
Solution Approach 2:
The patent segments the atopic dermatitis patient population into distinct subgroups based on IgE levels and genetic profiles. This segmentation allows the treatment protocol to be simplified for each subgroup - high-IgE patients receive tradipitant while low-IgE patients receive alternative therapies, reducing overall protocol complexity through clear stratification criteria
3Reliability
If higher dosages of tradipitant are administered, then treatment efficacy increases, but risk of adverse effects increases
Solution Approach 1:
The patent applies parameter changes by adjusting tradipitant dosage based on patient-specific parameters including baseline IgE levels, genotype, and treatment response. Dosage is optimized for each patient rather than using fixed dosing, allowing efficacy maximization while minimizing adverse effects through personalized dosage selection
Solution Approach 2:
The patent incorporates feedback mechanisms by monitoring patient response to tradipitant treatment and adjusting dosage accordingly. Treatment response assessment allows for dosage optimization - maintaining higher doses in responders who tolerate them well, while reducing or discontinuing in non-responders or those experiencing adverse effects
Data Source
AI summary
The disclosure relates to improved methods of treatment of atopic dermatitis and symptoms thereof with tradipitant.